N/A
N/A
Both
Gastric Intestinal Metaplasia
Trial Information
Study population and Sample size at Faculty of Medicine, Chulalongkorn University The
patients who were diagnosed gastric intestinal metaplasia from 1997 to 2012 and then follow
up for 5 years. Estimate sample size =280
- Investigational product, dosage & route of administration
- Questionnaire for explore the risk factors
- EGD with biopsy
- Blood sampling for gastro panel
- Duration of participation
- 5 years or until diagnose gastric cancer
Statistical method:
Unconditional-binary-logistic regression
Inclusion Criteria:
1. All patients were diagnosed GIM
2. All patients have to sign the consent form
Exclusion Criteria:
1. Previous gastric surgery including gastrectomy and bypass surgery
2. Bleeding tendency including decompensated cirrhosis, chronic kidney disease and
long-tem antiplatelets or anticoagulants
3. HIV infection
4. History of proton pump inhibitor use within 1 week
5. History of antibiotic use within 4 weeks
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
The prevalence of early gastric cancer in gastric intestinal metaplasia(GIM) patient from 5 year-follow-up in Thai population
Outcome Description:
In Thailand, gastric cancer patients usually presented with advance stage and carried the dismal prognosis. GIM is a well known precancerous lesion. The appropriate follow-up period in high risk GIM patient can increase the prevalence of early gastric cancer and reduce the mortality rate of gastric cancer
Outcome Time Frame:
Up to 5 years
Safety Issue:
Yes
Principal Investigator
Rungsun Rerknimitr, Professor
Investigator Role:
Study Director
Investigator Affiliation:
King Chulalongkorn Memorial Hospital
Authority:
Thailand: Ethical Committee
Study ID:
RP003
NCT ID:
NCT01490541
Start Date:
October 2011
Completion Date:
October 2017
Related Keywords:
- Gastric Intestinal Metaplasia
- Gastric intestinal metaplasia
- Metaplasia
- Gastritis, Atrophic
Name | Location |
|---|
